Skip to main content

Table 2 Outcomes by initial dosing strategy of thromboprophylaxis

From: Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients

  Total (n = 152) Initial dosing strategy of thromboprophylaxis p-valued
Low dosea (n = 67) Medium doseb (n = 48) High dose c (n = 37)
Primary outcome
 28-day mortality, No. (%) 43 (28.3) 26 (38.8) 12 (25.0) 5 (13.5) 0.02
Secondary outcomes
 ICU-free days alive during 28 days from ICU-admission, days 9 (0–21) 0 (0–20) 11 (0–19) 18 (0–26) 0.07
 Thromboembolic events < 28 days, No. (%) 22 (14.5) 12 (17.9) 9 (18.8) 1 (2.7) 0.04
  Pulmonary embolism, No. (%) 17 (11.2) 10 (14.9) 6 (12.5) 1 (2.7) 0.15
  Deep vein thrombosis, No. (%) 4 (2.6) 1 (1.5) 3 (6.3) 0 (0.0) 0.21
  Ischemic stroke, No. (%) 4 (2.7) 4 (6.0) 0 (0.0) 0 (0.0) 0.16
  Other thrombotic event, No. (%) 3 (2.0) 2 (3.0) 1 (2.1) 0 (0.0) 0.79
  Time to event, days 8 (6–17) 8 (6–20) 8 (6–10) 11 (11–11) 0.61
 Bleeding events < 28 days, No. (%) 16 (10.5) 8 (11.9) 7 (14.6) 1 (2.7) 0.16
  Cerebral parenchymal bleeding, No. (%) 2 (1.3) 2 (3.0) 0 (0.0) 0 (0.0) 0.50
  WHO bleeding assessment score
   Grade I—minor, No. (%) 8 (5.3) 3 (4.5) 4 (8.3) 1 (2.7) 0.58
   Grade II—moderate, No. (%) 3 (2.0) 2 (3.0) 1 (2.1) 0 (0.0) 0.79
   Grade III—major, No. (%) 2 (1.3) 1 (1.5) 1 (2.1) 0 (0.0) 0.99
   Grade IV—severe, No. (%) 3 (2.0) 2 (3.0) 1 (2.1) 0 (0.0) 0.79
  Time to bleeding event, days 13 (8–18) 16 (6–20) 11 (10–20) 1 (1–1) 0.36
Lab characteristics
 Fibrin-D-dimer, mg/L FEU, highest 3.2 (1.2–9.9) 6.4 (2.0–14.6) 2.8 (1.2–9.4) 1.7 (0.7–3.3) 0.002
 CRP, mg/L, highest 282 (183–381) 335 (200–423) 290 (201–385) 229 (162–319) 0.01
 Hemoglobin, g/L, lowest 98 (85–113) 94 (80–104) 102 (94–116) 107 (95–118) 0.01
 Creatinine, µmol/L, highest 82 (64–158) 100 (78–236) 78 (55–139) 66 (49–74)  < 0.001
 Platelet count, 109/L, lowest 239 (180–322) 203 (164–282) 257 (197–290) 314 (218–370) 0.003
 INR, highest 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.0 (1.0–1.1) 0.18
  1. Primary and secondary outcomes during the first 28 days among 152 patients admitted to the intensive care unit due to COVID-19 at Södersjukhuset, Stockholm, March 6 to April 30, 2020, by initial dosing strategy with tinzaparin/dalteparin as thromboprophylaxis
  2. Values are medians (interquartile range) unless otherwise indicated. p-values for differences across exposure categories were obtained using Fisher´s exact test for categorical, and Kruskal Wallis for continuous, data. CRP, C-reactive protein; ICU, intensive care unit; OD, once a day; IQR, interquartile range; WHO, World Health Organization
  3. aTinzaparin, 2500–4500 IU OD; or dalteparin, 2500–5000 IU OD
  4. bTinzaparin, > 4500 IU OD to < 175 IU/kg of body weight OD; or dalteparin, > 5000 IU OD to < 200 IU/kg of body weight OD
  5. cTinzaparin, ≥ 175 IU/kg of body weight OD; or dalteparin, ≥ 200 IU/kg of body weight OD
  6. dp values for differences across exposure categories were obtained using Fisher’s exact test for categorical and Kruskal–Wallis test for continuous data